The article discusses a report in January 7, 2015 issue of "Nature" magazine on an antibiotic drug candidate, called teixobactin, that was made by Kim Lewis and colleagues using isolates from the soil bacterium Eleftheria terrae, focusing on it works and when it will be ready for human ...
In addition to their antibacterial effectiveness, GmPcides appear to be less likely to lead to drug-resistant strains. Experiments designed to create resistant bacteria found very few cells able to withstand treatment and thus pass on their advantages to the next generation of bacteria. “...
It is common for critically ill patients to be given empirical intravenous (IV) antibiotic therapy upon admission due to rapid delivery, high bioavailability, and uncertainty surrounding a potential infection. Then later in the treatment regime once the patient is stabilized and the infection is ...
Short-Course Antibiotic Therapy for Meningitis in Children Shows Promise.Stapleton, F. Bruder
The UK Health Security Agency (UKHSA) has reported a confirmed case of antibiotic-resistantNeisseria gonorrhoeaein a heterosexual man living in the UK. The strain was resistant to ceftriaxone, which is now the standard first-line treatment for gonorrhoea, following years of rising resistance ofN go...
New Antibiotic May Combat Resistant Bacteria; Teixobactin Shows Promise in Early Experiments, Researchers SayThompson, Dennis
"Many things fall under the umbrella of proper and appropriate MRSA pneumonia treatment, and these results present a possible benefit with the use of CPT-F," says Samia Arshad, a Henry Ford Infectious Diseases epidemiologist and the study's lead author. "It is critical for us to find alterna...
Zosurabalpin is now in phase 1 clinical trial for use in patients infected with Crab. This early testing in humans will help the company developing the drug, Roche, to work out any side effects of the drugs as well as potential toxicity. Most importantly, they need to check that the dru...
Antibiotic Shows Promise in Serious Pediatric Skin InfectionsSteve Duffy
An abstract is unavailable.doi:10.1097/01.COT.0000294413.05372.5aGoodmanOncology Times